Skip to main content
SpringerLink
Log in

Pre-Exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE Study)

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

Tenofovir-emtricitabine (TDF–FTC) has demonstrated effectiveness as HIV preexposure prophylaxis (PrEP), but it is not commonly prescribed. Our study was designed to determine the barriers preventing utilization of PrEP among men who have sex with men (MSM), the group at greatest risk for HIV infection in the United States. A population-based sample of MSM presenting for HIV testing at ‘Early Test’ HIV testing and counseling sites in San Diego, California were offered PrEP and education about potential efficacy. Eligible individuals reported having unprotected sex within the past 12 months and who tested negative for HIV were offered study participation. Despite offering procedures for evaluation and prescription for PrEP to 416 eligible subjects, less than 0.5 % of participants received the drug. Surveys collected from 54 of those who declined study participation revealed multiple barriers to PrEP among MSM including cost, low perceived risk of infection and concerns about taking a daily medication and potential long-term side effects. Efforts should be made to address these barriers, especially lowering the cost of TDF–FTC, education about PrEP side effects and awareness of HIV risks.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Centers for Disease Control and Prevention. HIV in the United States: At a Glance. February 2013. http://www.cdc.gov/hiv/resources/factsheets/us.htm. Accessed March, 26 2012.

  2. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Anderson PL, Glidden DV, Liu A, Buchbinder S, Lama JR, Guanira JV, et al. Emtricitabine–tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125.

    Article  PubMed Central  PubMed  Google Scholar 

  4. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011 Jan 28;60(3):65–8.

  5. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34 Epub 2012 Jul 11.

    Article  CAS  PubMed  Google Scholar 

  7. Brooks RA, Landovitz RJ, Kaplan RL, Lieber E, Lee SJ, Barkley TW. Sexual risk behaviors and acceptability of HIV pre-exposure prophylaxis among HIV-negative gay and bisexual men in serodiscordant relationships: a mixed methods study. AIDS Patient Care STDs. 2012;26(2):87–94.

    Article  PubMed Central  PubMed  Google Scholar 

  8. Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2013;89(3):207–11.

    Article  PubMed  Google Scholar 

  9. Mustanski B, Johnson AK, Garofalo R, Ryan D, Birkett M. Perceived likelihood of using HIV pre-exposure prophylaxis medications among young men who have sex with men. AIDS Behav. 2013;17(6):2173–9.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Krakower D, Mayer KH. Engaging healthcare providers to implement HIV pre-exposure prophylaxis. Curr Opin HIV AIDS. 2012;7(6):593–9.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248–54. doi:10.1089/apc.2012.0419.

    Article  PubMed Central  PubMed  Google Scholar 

  12. County of San Diego Health and Human Services Agency Division of Public Health Services Epidemiology and Immunization Services Branch HIV/AIDS Surveillance Program Epidemiology Report 2012. http://www.sdcounty.ca.gov/hhsa/programs/phs/documents/HAEU_BiAnnual_Report_2012_final.pdf. Accessed 10 December, 2012.

Download references

Acknowledgment

This work was supported by the Veterans Affairs and grants from the National Institutes of Health: DA034978, AI69432, AI007384, AI080193, AI096113, AI090970, AI043638, MH62512, MH083552, AI077304, AI36214, AI047745, AI74621, AI080353, AI100665, GM093939; the International AIDS Vaccine Initiative; the James B. Pendleton Charitable Trust.

Author information

Authors and Affiliations

  1. University of California San Diego, 200 W. Arbor Dr., M/C 8425, La Jolla, CA, 92103, USA

    Helen L. King, Samuel B. Keller, Michael A. Giancola, David A. Rodriguez, Jasmine J. Chau, Jason A. Young, Susan J. Little & Davey M. Smith

  2. Veterans Administration San Diego Healthcare System, San Diego, CA, USA

    Davey M. Smith

Authors
  1. Helen L. King
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Samuel B. Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael A. Giancola
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. David A. Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jasmine J. Chau
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jason A. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Susan J. Little
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Davey M. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helen L. King.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOC 368 kb)

Supplementary material 2 (DOC 25 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

King, H.L., Keller, S.B., Giancola, M.A. et al. Pre-Exposure Prophylaxis Accessibility Research and Evaluation (PrEPARE Study). AIDS Behav 18, 1722–1725 (2014). https://doi.org/10.1007/s10461-014-0845-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-014-0845-5

Keywords

Search

Navigation